An allometric pharmacokinetic/pharmacodynamics model for BI 893923, a novel IGF-1 receptor inhibitor
BI 893923 is a novel IGF1R/INSR inhibitor with promising anti-tumor efficacy. Dose-limiting hyperglycemia has been observed for other IGF1R/INSR inhibitors in clinical trials. To counterbalance anti-tumor efficacy with the risk of hyperglycemia and to determine the therapeutic window, we aimed to develop a translational pharmacokinetic/pharmacodynamics model for BI 893923. This aimed to translate pharmacokinetics and pharmacodynamics from animals to humans by an allometrically scaled semi-mechanistic model.
Model development was based on a previously published PK/PD model for BI 893923 in mice (Titze et al., Cancer Chemother Pharmacol 77:1303–1314, 13). PK and blood glucose parameters were scaled by allometric principles using body weight as a scaling factor along with an estimation of the parameter exponents. Biomarker and tumor growth parameters were extrapolated from mouse to human using the body weight ratio as scaling factor.
The allometric PK/PD model successfully described BI 893923 pharmacokinetics and blood glucose across mouse, rat, dog, minipig, and monkey. BI 893923 human exposure as well as blood glucose and tumor growth were predicted and compared for different dosing scenarios. A comprehensive risk–benefit analysis was conducted by determining the net clinical benefit for each schedule. An oral dose of 2750 mg BI 893923 divided in three evenly distributed doses was identified as the optimal human dosing regimen, predicting a tumor growth inhibition of 90.4% without associated hyperglycemia.
Our model supported human therapeutic dose estimation by rationalizing the optimal efficacious dosing regimen with minimal undesired effects. This modeling approach may be useful for PK/PD scaling of other IGF1R/INSR inhibitors.
KeywordsPK/PD modeling Allometric scaling IGF1R/INSR inhibitor Net clinical benefit Human therapeutic dose estimation
Insulin-like growth factor
Net clinical benefit
Tumor growth inhibition
Duration of hyperglycemia
Visual predictive check
We thank the following colleagues for their excellent technical assistance: Ida Dinold, Norbert Eidkum, Stefan Fischer, Astrid Jeschko, Matthias Klemencic, Katharina Mayr, Reiner Meyer, Thomas Pecina, Christian Salamon, Michaela Streicher, and Susanne Wollner-Gaida.
Compliance with ethical standards
Conflict of interest
Thorsten Lehr has received research grants from Boehringer Ingelheim and is a consultant member of Boehringer Ingelheim. Otmar Schaaf, Marco H. Hofmann, Michael P. Sanderson, Stephan K. Zahn, and Jens Quant are employees of Boehringer Ingelheim.
All applicable international, national, and/or institutional guidelines for the care and use of animals were followed. All procedures performed in studies involving animals were in accordance with the ethical standards of the institution or practice at which the studies were conducted.
- 6.Puzanov I, Lindsay CR, Goff L, Sosman J, Gilbert J, Berlin J (2015) A phase I study of continuous oral dosing of OSI-906, a dual inhibitor of insulin-like growth factor-1 and insulin receptors, in patients with advanced solid tumors. Clin Cancer Res 21:701–711. doi: 10.1158/1078-0432.CCR-14-0303 CrossRefPubMedGoogle Scholar
- 7.Becerra CR, Salazar R, Garcia-Carbonero R, Thomas AL, Vázquez-Mazón FJ, Cassidy J et al (2014) Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial. Cancer Chemother Pharmacol 73:695–702. doi: 10.1007/s00280-014-2391-2 CrossRefPubMedGoogle Scholar
- 13.Titze MI, Schaaf O, Hofmann MH, Sanderson MP, Zahn SK, Quant J et al (2016) A comprehensive pharmacokinetic/pharmacodynamics analysis of the novel IGF1R/INSR inhibitor BI 893923 applying in vitro, in vivo and in silico modelling techniques. Cancer Chemother Pharmacol 77:1303–1314. doi: 10.1007/s00280-016-3049-z CrossRefPubMedGoogle Scholar
- 14.Sanderson MP, Apgar J, Garin-Chesa P, Hofmann MH, Kessler D, Quant J et al (2015) BI 885578, a novel IGF1R/INSR tyrosine kinase inhibitor with pharmacokinetic properties that dissociate anti-tumor efficacy and perturbation of glucose homeostasis. Mol Cancer Ther 14:2762–2772. doi: 10.1158/1535-7163.MCT-15-0539 CrossRefPubMedGoogle Scholar
- 15.Beal S, Sheiner L, Boeckmann A, Bauer R. NONMEM Users Guide. Icon Dev Solut Ellicott City, Maryland, USA 1998Google Scholar
- 19.ICRP P (2002) Ann ICRP 32:1–277Google Scholar
- 20.NIH. Common Terminology Criteria for Adverse Events (CTCAE) 2009:45. http://evs.nci.nih.gov/ftp1/CTCAE/Archive/CTCAE_4.02_2009-09-15_QuickReference_8.5x11.pdf. Accessed 6 Aug 2015
- 23.Minipigs EG (2009) Organ weight Ellegaard Göttingen Minipigs 2009:1–12. http://minipigs.dk/the-goettingen-minipig/background-data/. Accessed 6 March 2014
- 25.Simeoni M, Magni P, Cammia C, De Nicolao G, Croci V, Pesenti E et al (2004) Predictive pharmacokinetic-pharmacodynamic modeling of tumor growth kinetics in xenograft models after administration of anticancer agents. Cancer Res 64:1094–1101. doi: 10.1158/0008-5472.CAN-03-2524 CrossRefPubMedGoogle Scholar
- 26.Elassaiss-schaap J (2010) Allometric scaling in oncology disease progression from xenograft tumor growth to human non-small-cell lung cancer. PAGE, BerlinGoogle Scholar
- 30.Danhof M, Jongh J De, Lange ECM De, Pasqua O Della, Ploeger BA, Voskuyl RA (2007) Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu Rev Pharmacol Toxicol 47:357–400. doi: 10.1146/annurev.pharmtox.47.120505.105154 CrossRefPubMedGoogle Scholar